The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for fedratinib (Celgene), an investigational agent being developed for the treatment of myelofibrosis (MF). Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).…
Models developed for individuals in whom aspirin is being considered for primary prevention of CVD.
The use of plasma infusion therapies (often called “vampire” treatments, in which people undergo infusions of a young donor’s blood) is on the rise across the United States.
The study authors utilized a variety of search engines to obtain randomized and quasi-randomized trials assessing the efficacy of various medical interventions used in the treatment of traumatic hyphema following closed-globe trauma.
The study authors identified 43 case reports as well as 8 case series discussing drug-induced thrombocytosis.
The expanded approval was supported by data from the Phase 2 multicenter, single-arm CA180-372 study (NCT01460160) which included 78 pediatric patients with newly diagnosed B-cell precursor Ph+ ALL.
The researchers found that phlebitis was the most common complication (44%), followed by infiltration (16.3%), occlusion (7.6%), and catheter dislodgement (5.6%).
The risk for herpes zoster (zoster) is elevated during the two years preceding diagnosis and during treatment of hematological cancer.
From May 1 2018 to July 31 2018, 5 cases of death associated with DS in patients taking Idhifa have been reported; in 2 of these cases, DS was listed as the only cause of death.
Xospata was evaluated in the Phase 3 open-label, multicenter, randomized ADMIRAL trial (N=138) which included patients with relapsed or refractory AML with a FLT3 ITD, D835, or I836 mutation.
